Hitachi Chemical Diagnostics Systems

Lab Reagents

Hitachi Exocomplete Laboratories manufactures the hitachi chemical diagnostics systems reagents distributed by Genprice. The Hitachi Chemical Diagnostics Systems reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Hitachi Exocomplete. Other Hitachi products are available in stock. Specificity: Hitachi Category: Chemical Group: Diagnostics Systems

Diagnostics Systems information

Recombinant Clostridium Acetobutylicum Chemical-Damaging Agent Resistance Protein B (aa 1-139)
VAng-Lsx7513-1mgEcoli 1 mg (E. coli)
EUR 3291
Description: Clostridium Acetobutylicum Chemical-damaging agent resistance protein B, recombinant protein.

Recombinant Clostridium Acetobutylicum Chemical-Damaging Agent Resistance Protein B (aa 1-139)
VAng-Lsx7513-500gEcoli 500 µg (E. coli)
EUR 2226
Description: Clostridium Acetobutylicum Chemical-damaging agent resistance protein B, recombinant protein.

Recombinant Clostridium Acetobutylicum Chemical-Damaging Agent Resistance Protein B (aa 1-139)
VAng-Lsx7513-50gEcoli 50 µg (E. coli)
EUR 1524
Description: Clostridium Acetobutylicum Chemical-damaging agent resistance protein B, recombinant protein.

Recombinant Clostridium Acetobutylicum Chemical-Damaging Agent Resistance Protein C (aa 1-101)
VAng-Lsx7514-1mgEcoli 1 mg (E. coli)
EUR 3630
Description: Clostridium Acetobutylicum Chemical-damaging agent resistance protein C, recombinant protein.

Recombinant Clostridium Acetobutylicum Chemical-Damaging Agent Resistance Protein C (aa 1-101)
VAng-Lsx7514-500gEcoli 500 µg (E. coli)
EUR 2460
Description: Clostridium Acetobutylicum Chemical-damaging agent resistance protein C, recombinant protein.

Recombinant Clostridium Acetobutylicum Chemical-Damaging Agent Resistance Protein C (aa 1-101)
VAng-Lsx7514-50gEcoli 50 µg (E. coli)
EUR 1676
Description: Clostridium Acetobutylicum Chemical-damaging agent resistance protein C, recombinant protein.

SEALING MAT, FOR 384 WELL DEEP WELL MICROPLATE, POLYPROPYLENE, CHEMICAL RESISTANT, NONSTERILE, BULK
3341 10/pk
EUR 330
Description: Storage; Storage Mats

SEALING MAT, IMPERMAMAT, FOR 96 WELL MICROPLATES WITH ROUND WELLS, CHEMICAL RESISTANT SILICONE, NATURAL, NONSTERILE, BULK
AM-2ML-RD-IMP 10/pk
EUR 234
Description: Sealing Products; Sealing mats - Axygen

SEALING MAT, IMPERMAMAT, FOR 384 DEEP WELL MICROPLATES, SQUARE WELLS, CHEMICAL RESISTANT SILICONE, NATURAL, NONSTERILE, BULK
AM-384-SQ-IMP 10/pk
EUR 234
Description: Sealing Products; Sealing mats - Axygen

SEALING MAT, IMPERMAMAT, FOR 2.0 ML 96 DEEP WELL MICROPLATES, SQUARE WELLS, CHEMICAL RESISTANT SILICONE, NATURAL, NONSTERILE, BULK
AM-2ML-SQ-IMP 10/pk
EUR 234
Description: Sealing Products; Sealing mats - Axygen

SEALING MAT, IMPERMAMAT, FOR 2.0 ML 96 DEEP WELL MICROPLATES, SQUARE WELLS, CHEMICAL RESISTANT SILICONE, NATURAL, STERILE, BULK
AM-2ML-SQ-IMP-S 10/pk
EUR 249
Description: Sealing Products; Sealing mats - Axygen

SEALING MAT, IMPERMAMAT, FOR 5.0 ML 48 DEEP WELL PLATES, RECTANGULAR WELLS, CHEMICAL RESISTANT SILICONE, NATURAL, NONSTERILE, BULK
AM-48-IMP 10/pk
EUR 234
Description: Sealing Products; Sealing mats - Axygen

SARS-CoV-2 Rapid Antigen Test Nasal
9901-NCOV-03G 25 Tests/Kit
EUR 94
  • Test type: Qualitative
  • Sample type: Nasal swab
  • Target antigen: Nucleocapsid (N)
  • Time to result: 15 minutes (Readout window 15 - 30 minutes)
  • Stability (test, opened pouch): 1 hour once the test has been opened
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

Mouse Anti-Human CD57 monoclonal antibody, clone JID650
CABT-L2966-100uL500uL 100 uL, 500 uL
EUR 502

Mouse Anti-Human Uroplakin III monoclonal antibody, clone JID792
CABT-L2967-100uL500uL 100 uL, 500 uL
EUR 502

Mouse Anti-Human HPV16 monoclonal antibody, clone JID714
CABT-L2968-100uL500uL 100 uL, 500 uL
EUR 502

Mouse Anti-Human CD3 monoclonal antibody, clone JID645
CABT-L2969-100uL500uL 100 uL, 500 uL
EUR 502